Many neuroprotective agents, some promising, have been tested as adjunctive therapy with tPA to reduce its Background and Purpose-Taurine (2-aminoethansulfolic amino acid) exerts neuroprotective actions in experimental stroke. Here, we investigated the effect of taurine in combination with delayed tPA (tissue-type plasminogen activator) on embolic stroke. Methods-Rats subjected to embolic middle cerebral artery occlusion were treated with taurine (50 mg/kg) at 4 hours in combination with tPA (10 mg/kg) at 6 hours. Control groups consisted of ischemic rats treated with either taurine (50 mg/ kg) or saline at 4 hours or tPA (10 mg/kg) alone at 2 or 6 hours after middle cerebral artery occlusion. Results-We found that combination treatment with taurine and tPA robustly reduced infarct volume and neurological deficits 3 days after stroke, whereas treatment with taurine alone had a less-significant protective effect. tPA alone at 6 hours had no effects on infarct volume but instead induced intracerebral hemorrhage. The combination treatment with taurine prevented tPA-associated hemorrhage and reduced intravascular deposition of fibrin/fibrinogen and platelets in downstream microvessels and hence improved microvascular patency. These protective effects are associated with profound inhibition of CD147 (cluster of differentiation 147)-dependent MMP-9 (matrix metalloproteinase-9) pathway in ischemic brain endothelium by taurine. Notably, targeted inhibition of CD147 by intracerebroventricular injection of the rat CD147 siRNA profoundly inhibited ischemia-induced and tPA-enhanced MMP-9 activity in ischemic brain endothelium and blocked tPA-induced cerebral hemorrhage. Finally, the combination treatment with taurine and tPA improved long-term outcome at least 45 days after stroke compared with saline-treated group. Conclusions-Our results suggest that taurine in combination with tPA may be a clinically feasible approach toward future attempts at combination stroke therapy. Visual Overview-An online visual overview is available for this article. 
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troke is a leading cause of death and permanent disability worldwide. To date, intravenous administration of tPA (tissue-type plasminogen activator; IV tPA) remains the only Food and Drug Administration-approved drug therapy for achieving cerebral reperfusion, but its use is given to only 3% to 8.5% of stroke cases in the United States. 1 This is mainly related to increased risks of intracranial hemorrhage. 1 It is well recognized that IV tPA beyond 3 hours of stroke onset significantly increases cerebral bleeding although it could be extended to a 3-to 4.5-hour time window in carefully selected patients. 2 Thus, there is great interest in developing adjuvant drugs to use with tPA to extend its treatment time window to a broader patient population.
Taurine (2-aminoethansulfolic amino acid) is the most abundant endogenous sulfur-containing amino acid in animals and humans. It has many important biological functions in the body, such as bile acid conjugation, osmoregulation, antiinflammation, anti-oxidation, membrane stabilization, and calcium homeostasis. 3 Taurine has been shown to be neuroprotective through multiple mechanisms of action in acute ischemic stroke and traumatic brain injury. 4, 5 For example, taurine can downregulate ischemia/hypoxia-and glutamateinduced neuronal apoptosis by suppressing endoplasmic reticulum stress and maintaining intracellular Ca 2+ homeostasis. 6, 7 Taurine can also suppress ischemic inflammation in the brain by reducing cytokine production and neutrophil infiltration by inhibition of NF-κB (nuclear factor-κB) pathway.
neurotoxicity, risk of hemorrhage, and reperfusion injury in an effort to increase its neuroprotection and therapeutic time window; however, few have proven to be efficacious in clinical trials. 9, 10 Compared with other neuroprotective agents, taurine may have several unique advantages: (1) taurine has many important endogenous biological functions; (2) taurine-an organic compound with small molecular weight (125 Da)-can readily cross the blood-brain barrier (BBB) into brain parenchyma 11 ; (3) the pharmacokinetics and metabolism of taurine is well characterized in both animals and humans and ≈3000 mg per day of taurine as supplementation is generally recommended. At this dose, excess taurine can be excreted by the kidneys with minimal toxicity. 3 In clinical practice, taurine supplementation is considered to be safe and helpful as an adjuvant therapy for congestive heart failure, high blood pressure, and diabetes mellitus. [12] [13] [14] Based on these unique advantages, multiple health benefits, and limited side effects, we proposed taurine as an ideal neuroprotective agent for combined therapy with IV tPA. In this study, we aimed to determine whether and how taurine extends the therapeutic time window for IV tPA in a rat model of embolic stroke.
Materials and Methods
Data supporting the findings of this study are available from the corresponding author on reasonable request. This article adheres to the American Heart Association Journals' implementation of the Transparency and Openness Promotion Guidelines. All experimental protocols were approved by the Institutional Animal Care and Use Committee at Louisiana State University Health Science Center Shreveport and Penn State University College of Medicine. A detailed Methods section is provided in the online-only Data Supplement. The checklist of methodological and reporting aspects is shown in Table  I in the online-only Data Supplement. A diagram of the experimental design and animal groups is shown in Figure I in the online-only Data Supplement. The number of animals used in each experimental treatment group is summarized in Table II in the online-only Data Supplement.
Stroke Model
Sprague-Dawley rats (male, weighing 280-340 g) were subjected to embolic middle cerebral artery occlusion (MCAO) according to the standard operating procedure in our laboratory.
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Experimental Protocols
Ischemic rats were randomly assigned to the following treatment or control groups: treated with 0.9% saline as a vehicle, early tPA at 2 hours, delayed tPA at 6 hours, taurine at 4 hours, or taurine at 4 hours plus tPA at 6 hours. All stroke outcome measurements were performed by investigators blinded to the treatments. Human recombinant tPA (Alteplase; Genentech, Inc, San Francisco, CA) was intravenously administered at a dose of 10 mg/kg (10% as a bolus and 90% as a 30-minute infusion) using a syringe infusion pump (Harvard Apparatus, Holliston, MA). Alteplase of 10 mg/kg is a standard dose typically used in rodents. [16] [17] [18] Taurine (T0625-Sigma-Aldrich; purity, >99%; molecular weight, 125.15 Da) at a dose of 50 mg/kg (dissolved in 0.9% saline) per day was intravenously administered starting 4 hours after MCAO. Published studies have shown that taurine at a dose of 40 to 50 mg/kg per day exerts potent neuroprotection in a filament MCAO model in rats. 19, 20 The effects of taurine on tPAinduced brain hemorrhage and acute stroke injury were examined at 3 days, in which taurine was given once daily. The effects of taurine on long-term outcomes were assessed ≤45 days after stroke, in which taurine was given once daily for the first 7 days. In some experiments, intracerebroventricular injection of CD147 (cluster of differentiation 147), siRNA, or scramble control siRNA (sc-siRNA) was performed ( Figure II in the online-only Data Supplement) as described previously (please see Methods in the online-only Data Supplement for detail).
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Infarct Volume, Intracerebral Hemorrhage, BBB Permeability, and Neurological Deficits Infarct volume was measured in TTC-stained coronal sections on day 3 after MCAO. 22 Hemoglobin levels were measured in the TTCstained sections by a spectrophotometric assay using Drabkin reagent (Sigma-Aldrich). 23 It has been shown that hemoglobin measurements can be simultaneously performed on TTC-stained sections. 24 The modified Bederson score 25 (global neurological function), foot-fault test 26 (motor impairment and forelimb coordination), and modified neurological severity score 27 (a composite of motor, sensory, reflex, and balance tests) were performed by a blinded investigator. In a separate set of experiment, early impairment of the BBB permeability was determined by measuring the extravasation of Evans blue dye (Sigma-Aldrich) in the brain tissue 12 hours after MCAO.
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Western Blot and Gelatin Zymography
Protein extracts were obtained from the cerebral cortices (bregma +1 to −2 mm) and the isolated cerebral microvessels ( Figure IIIA in the online-only Data Supplement). These assays were performed as described previously.
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Immunohistochemistry
Immunohistochemistry was performed as described previously. 22, 28 The number of vessels positively stained with fibrin/fibrinogen and thrombocytes was counted in the ischemic boundary zone ( Figure  IIIB in the online-only Data Supplement). The gelatinase (MMP-2/ MMP-9 [matrix metalloproteinase-2/matrix metalloproteinase-9]) activity in brain tissue was detected by in situ zymography (ISZ). All immunostaining data were analyzed by a blinded investigator, and data are presented as the density of immunoreactive vessels relative to the imaged area (mm 2 ). Cerebral microvascular patency was assessed using the fluorescein isothiocyanate-labeled dextran method.
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Statistical Analysis
Data are expressed as mean±SE of the mean. The GraphPad Prism 5 software package was used for statistical analysis. The normality of data was assessed with the D'Agostino-Pearson omnibus test. For normally distributed variables, 1-way ANOVA followed by the Bonferroni post hoc test was used to assess differences between groups. If only 2 groups were compared, an unpaired, 2-tailed Student t test was applied. The KruskalWallis and Mann-Whitney U tests were used to explore differences between groups in non-normally distributed variables. Nonparametric functional outcome scores were compared by Kruskal-Wallis test with post hoc Dunn corrections. For comparison of survival data, the log-rank test was used. P<0.05 was considered statistically significant.
Results
Effects of Taurine on tPA-Induced Intracerebral Hemorrhage and Acute Stroke Outcome
As expected, early IV tPA at 2 hours reduced infarct volume, and delayed IV tPA at 6 hours had no effect on infarct volume but instead promoted intracerebral hemorrhage ( Figure 1A and 1B). Taurine alone at 4 hours had no detectable effect on hemorrhage, but the combination treatment with taurine profoundly reduced tPA-associated hemorrhage. Moreover, the combination treatment with taurine and delayed tPA was more effective than the treatment with taurine alone in reducing infarct volume ( Figure 1B ) and neurological deficits ( Figure 1C ) 3 days after stroke. Neurological deficits were determined by the Bederson score and the foot-fault test ( Figure 1C ). Physiological parameters remained within
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July 2018 normal range in all experimental groups (Table III in the online-only Data Supplement). In this model, the 3-day mortality rates in stroke rats treated with saline, early tPA (at 2 hours), late tPA (at 6 hours), taurine (at 4 hours), and taurine (at 4 hours) plus tPA (at 6 hours) were 29%, 17%, 47%, 20%, and 21%, respectively. But because of the limited animal numbers studied here, there were no statistically significant differences between these groups (Table IV in the online-only  Data Supplement) . Early disruption of the BBB after thrombolytic therapy predicts hemorrhage in patients with acute stroke. 29 Therefore, we additionally investigated the effect of taurine on ischemiainduced and tPA-enhanced early impairment of BBB permeability assessed by Evans blue extravasation at 12 hours after stroke onset (ie, 6 hours after delayed tPA). Evans blue extravasation into the brain parenchyma was at similar low levels in the saline-and taurine-alone groups but dramatically increased (>20-fold) in the tPA-alone group, and importantly, the tPA-associated increase was significantly reduced by cotreatment with taurine at 4 hours after onset of ischemia ( Figure 1D ). As expected, Evans blue extravasation was not visualized in the sham-operated brain.
Effects of Taurine on tPA-Enhanced MMP-9 Activity in Ischemic Brain Microvessels
Increased MMPs (matrix metalloproteinases), in particular MMP-9, plays a pivotal role in tPA-induced hemorrhage after stroke. 30 ISZ was performed to assess gelatinase (MMP-2/MMP-9) activity in the brain at 24 hours after stroke. Gelatinatic activity was low in sham-operated brain but significantly induced by MCAO and further augmented by delayed IV tPA (Figure 2A and 2B) . Combination treatment with taurine markedly reduced ischemia-induced and tPA-enhanced gelatinolytic activity. Notably, taurine almost completely abolished gelatinolytic activity in ischemic brain microvessels (Figure 2A and 2B) . Next, gelatin zymography was performed to assess MMP profiles in brain microvessels isolated at 24 hours after stroke. MMP-9 activity was significantly increased by ischemia and further enhanced by delayed tPA, and these effects were profoundly inhibited by taurine, whereas MMP-2 activity was rarely detectable in sham control and also not altered by either ischemia, tPA, or taurine ( Figure 2C and 2D) .
Effects of Taurine on tPA-Enhanced CD147 Expression in Ischemic Brain Microvessels
We have reported that CD147 is rapidly increased in ischemic brain endothelium after MCAO in mice. 28 Here, we examined CD147 expression after embolic stroke in rats. Immunohistochemistry showed that MCAO robustly induced CD147 expression in ischemic brain endothelium and that was further augmented by delayed administration of tPA ( Figure 3A ). Double immunostaining confirmed that CD147 immunoreactivity colocalized almost exclusively with brain microvessels (marked by endothelial barrier antigen; Figure 3B ). Notably, the ischemia-induced and tPA-enhanced CD147 expression was profoundly inhibited by taurine ( Figure 3A) . These findings were solidly verified by Western blot analysis of CD147 protein in brain microvessels isolated at 24 hours after stroke ( Figure 3C ). Moreover, we found that tPA (20 µg/mL) robustly stimulated CD147 expression in cultured rat brain microvascular endothelial cells exposed Figure 2 . Taurine (Tau) inhibits tPA (tissue-type plasminogen activator)-enhanced gelatinolytic activity in ischemic brain microvessels 24 hours after stroke. A, Representative images of in situ zymography in fresh-frozen brain sections in the indicated groups. Images were acquired from peri-infarct cortex (bar=50 μm). B, Semiquantification of gelatinolytic activity was analyzed by green fluorescence intensity. Data were presented as fold change relative to saline-treated group. n=5 per group. ***P<0.001 vs saline; +++P<0.001 vs tPA (6 hours). C, Representative images of gelatin zymography for MMP-2/MMP-9 (matrix metalloproteinase-2/ matrix metalloproteinase-9) activity using isolated brain microvessels (a pool of 3 rats per group). D, Semiquantification of MMP-9 bands was analyzed by densitometry. Std: standard human MMP-2/MMP-9 mixed marker. Data are mean±SEM from 3 independent experiments. **P<0.01, ***P<0.001 vs saline; +++P<0.001 vs tPA (6 hours).
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to oxygen and glucose deprivation, and this effect was dosedependently inhibited by taurine ( Figure 3D ).
Effects of CD147 Expression on tPA-Induced Intracerebral Hemorrhage Associated With Cerebral Microvascular MMP-9 Activity
Subsequently, we determined whether CD147 is important for tPA-induced MMP-9 and hemorrhagic transformation. CD147 siRNA, sc-siRNA, or siRNA delivery reagent only (as vehicle) was infused into the lateral ventricles in the ipsilateral hemisphere by intracerebroventricular injection within 1 hour after ischemia onset ( Figure IIA in the onlineonly Data Supplement). The injected siRNA was localized to cytoplasmic compartments with perinuclear location (marked by 4',6-diamidino-2-phenylindole; Figure IIB in the onlineonly Data Supplement). Western blot analysis showed that CD147 siRNA markedly reduced CD147 protein levels in the ischemic cortex, but sc-siRNA had no effect ( Figure 4A ). ISZ showed that CD147 siRNA, but not sc-siRNA, decreased the number of ISZ-positive vessels in the ischemic cortex ( Figure 4B ). Furthermore, gelatin zymography analysis of isolated brain microvessls showed that CD147 siRNA, but not sc-siRNA, suppressed MMP-9 activity ( Figure 4C) . Notably, the siRNA-mediated inhibition of CD147 in the brain almost completely blocked delayed tPA-induced brain hemorrhage ( Figure 4D ). Moreover, similar effects were observed 
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between the taurine alone, CD147 siRNA alone, and taurine plus CD147 siRNA treatments, with respect to inhibition of MMP-9 examined either by ISZ ( Figure 4B ) or by gelatin zymography ( Figure 4C ), as well as to the delayed tPAinduced hemorrhage ( Figure 4D ). These results support our hypothesis that taurine blocks the tPA-associated hemorrhage through inhibition of a CD147-dependent MMP-9 pathway in ischemic brain endothelium after ischemic stroke.
Effects of Taurine on Microvascular Thrombus Formation and Cerebral Vascular Patency
Intravascular fibrin/fibrinogen deposition and platelet accumulation are 2 major factors contributing to secondary microvascular thrombus formation after ischemic stroke. 31 Double immunofluorescence staining was performed to examine intravascular fibrin/fibrinogen and thrombocyte/platelet deposition in cerebral microvessels (marked by endothelial barrier antigen). Fibrin/fibrinogen ( Figure 5A ) and thrombocytes/ platelets ( Figure 5B ) were rarely detected in sham-operated, nonischemic rats and also minimally detected within the saline-treated stroke rats possibly because of low cerebral perfusion in downstream microvessels without tPA thrombolysis in this stroke model induced by blood clots. However, both the fibrin/fibrinogen deposition and platelet accumulation in downstream microvessels were markedly increased in stroke rats with delayed tPA, and these increases were profoundly inhibited by combination treatment with taurine ( Figure 5A and 5B). Consistent with these findings, microvascular patency (determined by cerebral area perfused with fluorescein isothiocyanate-dextran) markedly dropped <25% of the baseline (sham) in the saline-treated rats, but it restored to 50% and 70% of baseline in stroke rats with delayed tPA alone or in combination with taurine, respectively ( Figure 5C and 5D).
Effects of Taurine in Combination With Delayed tPA on Long-Term Stroke Outcome
Although taurine's neuroprotection has been well documented in experimental stroke, all previous studies were performed only in the early phase (1-4 days) after stroke. 6, 8, 19, 20 Here, we investigated whether taurine's neuroprotection remains significant during longer periods of time after stroke. Cortical width index is used as a measure of brain atrophy as described previously. 17, 32 Severe brain atrophy was observed in the salinetreated stroke rats at 45 days after stroke. Treatment with taurine alone increased cortical width index by 27%, and the combined treatment with taurine and tPA increased cortical width index by 45%; in contrast, tPA alone showed no significant effect on cortical width index ( Figure 6A and 6B) . Consistent with these findings, taurine in combination with tPA significantly improved neurological functions, whereas taurine alone was less effective, as determined by the modified neurological severity score and foot-fault test within the 45 days of follow-up ( Figure 6C and  6D) . As expected, tPA alone did not exert any beneficial neurological effects when it was administered 6 hours after stroke. In this model, the 45-day mortality rates in MCAO rats treated with saline, tPA (at 6 hours), taurine (at 4 hours), and taurine (at 4 hours) plus tPA (at 6 hours) were 47%, 55%, 43%, and 31%, respectively. But because of the limited animal numbers studied here, there are no statistically significant differences between these groups (Table V in the online-only Data Supplement).
Discussion
The present study, for the first time, demonstrates that combination treatment with taurine at 4 hours extends the 
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July 2018 therapeutic time window of thrombolysis with tPA to 6 hours and improves long-term neurological outcome in the rat after embolic stroke. Mechanistically, we have found 2 important and previously undescribed beneficial actions of taurine for ischemic stroke. First, taurine may reduce the risk of hemorrhagic transformation associated with delayed tPA by suppressing the CD147-dependent MMP-9 pathway in ischemic brain endothelium. Second, taurine may improve the efficacy of thrombolytic therapy by reducing secondary thrombus formation in downstream microvessels and hence ameliorating cerebral vascular patency. Among currently available stroke models, the embolic MCAO is the most suitable for preclinical investigation of thrombolytic therapy. 33 In this study, we investigated whether and how taurine extends the therapeutic time window for IV tPA, using combined treatment with taurine at 4 hours and tPA at 6 hours after embolic MCAO in the rat. This combination modality is appropriate and has been previously established to extend the therapeutic window for tPA to 6 hours after embolic MCAO in rats with other neuroprotective agents, such as atorvastatin, minocycline, and the proteasome inhibitor ps-519. 16, 34, 35 The therapeutic window of tPA is 2 to 3 hours after embolic MCAO in rodents. It has been shown that a standard rodent dose of tPA (10 mg/kg) lost its effectiveness beyond 4 hours after embolic MCAO in rats and instead increased infarct volume, as well as hemorrhagic transformation. 36 Treatment with neuroprotective agents before IV tPA could block ischemic core enlargement and salvage the penumbra as early as possible. This approach might increase the number of patients with acute stroke eligible for tPA beyond the 4.5-hour window.
In the present study, the taurine alone treatment caused a mild reduction (≈15%) in infarct volume, thus the beneficial effect of taurine on tPA's side effects could not be simply explained by smaller infarct lesions. Because the extents of infarct size, BBB damage, and secondary microvascular thrombosis are all associated with the development of ischemic brain injury and neurological outcome, we think that the multiple beneficial actions, including profound reductions in infarct size and early BBB disruption, as well as reduced microvascular thrombosis associated with improved cerebral perfusion, which are conferred by the taurine and tPA combination rather than taurine alone, collaboratively contribute to the neuroprotection in acute stroke injury and long-term neurological recovery observed in this study.
The brain endothelium is a major target for tPA-induced BBB breakdown and hemorrhage in acute stroke. The results of the present study indicate that taurine exerts antihemorrhagic actions by primarily targeting the brain endothelium. tPA has been shown to directly activate MMP-9 in the brain endothelium by acting through LRP (low-density lipoprotein receptorrelated protein). 37, 38 In this study, we have found that taurine inhibits tPA-induced brain hemorrhage by interfering with the CD147-dependent MMP-9 pathway in brain endothelium. CD147 is a transmembrane glycoprotein, originally described as an inducer of MMPs. Increased expression of CD147 has been implicated in many human diseases, such as cancer, cardiovascular diseases, and neurological disorders. 39 We have reported that CD147 expression in brain endothelium was rapidly increased after ischemic stroke, and inhibition of CD147 with a function-blocking antibody attenuates BBB disruption by inhibiting MMP-9 in brain endothelium. 28 The results of the present study further reveal a previously undescribed role for CD147 in tPA-induced hemorrhagic transformation by driving MMP-9 activation in brain microvascular endothelial cells after ischemic stroke that can be inhibited by taurine.
Secondary microvascular thrombosis is an obstacle hindering the efficacy of thrombolytic therapy for patients with acute stroke, but there is no effective treatment. 40, 41 A subset of patients with stroke, despite successful thrombolysis, still exhibit progressive neurological deterioration that is likely related to incomplete reperfusion resulting from microvascular thrombosis. 40, 41 Prevention of secondary microvascular thrombosis associated with early reperfusion is considered to be essential for successful neuroprotection in stroke. 31, 42 The results of the present study show that taurine exerts potent antithrombotic effects by reducing intravascular fibrin and platelet deposition, which in turn reduces downstream microvascular thrombosis and improves cerebral vascular patency. Inhibition of NF-κB and CD147 is probably involved in the mechanisms of microvascular protection by taurine. Taurine is known to inhibit activation of NF-κB in the brain after ischemic stroke. 4, 8 It has been shown that upregulation of NF-κB-dependent PAI-1 (plasminogen activator inhibitor-1) pathway in brain endothelium promotes intravascular fibrin and platelet deposition after ischemic stroke. 43, 44 CD147 has been shown to promote platelet rolling, aggregation, and thrombus formation by interacting with platelet GP VI (glycoprotein VI). 45, 46 We have recently shown that inhibition of CD147 decreased intravascular fibrin and platelet deposition, which in turn reduced microvascular thrombosis after acute ischemic stroke. 28 On the basis of these observations, we propose that increased CD147 expression in ischemic brain endothelium may promote intravascular platelet accumulation by interacting with platelet GP VI, thereby contributing to microvascular thrombus formation that was inhibited by taurine to improve microvascular patency after thrombolysis with tPA.
In conclusion, our data suggest that taurine in combination with tPA may be a clinically feasible approach toward future attempts at combination stroke therapy.
Future Direction
Stroke Therapy Academic Industry Roundtable recommends that after initial evaluations in young, healthy male animals, further studies should be performed in females, aged animals, and animals with comorbid conditions, such as hypertension and diabetes mellitus. 47 In clinical practice, taurine has been used as an adjuvant therapy for these stroke-related diseases. The therapeutic effects of taurine therapy alone and with tPA in aged rats and rats with comorbid conditions (hypertension and diabetes mellitus) are currently under investigation in our laboratory.
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